Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...

Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...

Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda ...

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

Merck (MRK) announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or ...

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...

Merck's KEYLYNK-001 trial showed Keytruda and Lynparza improved progression-free survival in BRCA non-mutated ovarian cancer patients. In the waveLINE-007 trial, zilovertamab vedotin with R-CHP ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...